|
Market Closed -
Nasdaq Stockholm
09:30:00 16/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 12.74 SEK | -1.55% |
|
-7.55% | -57.67% |
| 16/09 | 11 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange | FW |
| 14/09 | US Regulator Accepts Orexo's New Drug Application for Anaphylaxis Treatment | MT |
Company Valuation: Orexo AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,184 | 648.2 | 532.1 | 603.8 | 1,039 | 444.9 | - | - |
| Change | - | -45.27% | -17.9% | 13.47% | 72% | -57.16% | - | - |
| Enterprise Value (EV) 1 | 1,173 | 791.1 | 809.5 | 940.6 | 609.4 | 339.9 | 444.9 | 441.9 |
| Change | - | -32.54% | 2.33% | 16.19% | -35.21% | -44.22% | 30.89% | -0.67% |
| P/E | -5.3x | -3.65x | -4.14x | -2.97x | 1.63x | -1.22x | -1.75x | -1.64x |
| PBR | 3.39x | 3.34x | 9.03x | -4.78x | 2.43x | 2.89x | - | -91x |
| PEG | - | 0.2x | 0.1x | -0.1x | -0x | 0x | 0.1x | -0.24x |
| Capitalization / Revenue | 2.1x | 1.04x | 0.83x | 1.02x | 1.98x | 23.4x | 16.5x | 13.5x |
| EV / Revenue | 2.08x | 1.27x | 1.27x | 1.59x | 1.16x | 17.9x | 16.5x | 13.4x |
| EV / EBITDA | -7.28x | -6.87x | -24.9x | 19.2x | 0.79x | -1.18x | -1.83x | -1.69x |
| EV / EBIT | -5.48x | -4.3x | -7.39x | -22.8x | 0.86x | -1.06x | -1.64x | -1.52x |
| EV / FCF | -4.16x | -4.38x | 7.65x | -24.8x | -3.12x | -0.9x | -2x | -1.86x |
| FCF Yield | -24% | -22.8% | 13.1% | -4.03% | -32.1% | -111% | -49.9% | -53.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -6.51 | -5.17 | -3.73 | -5.89 | 18.46 | -10.47 | -7.28 | -7.78 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 565 | 624.3 | 638.8 | 590 | 525.1 | 19 | 27 | 33 |
| EBITDA 1 | -161 | -115.2 | -32.5 | 48.9 | 772.3 | -288 | -243 | -262 |
| EBIT 1 | -214.1 | -183.9 | -109.5 | -41.2 | 705.3 | -321 | -272 | -290 |
| Net income 1 | -223.5 | -177.6 | -128.3 | -203 | - | -375 | - | -289.3 |
| Net Debt 1 | -11.7 | 142.9 | 277.4 | 336.8 | -429.2 | -105 | - | -3 |
| Reference price 2 | 34.50 | 18.86 | 15.46 | 17.50 | 30.10 | 12.74 | 12.74 | 12.74 |
| Nbr of stocks (in thousands) | 34,328 | 34,368 | 34,421 | 34,505 | 34,505 | 34,922 | - | - |
| Announcement Date | 27/01/22 | 26/01/23 | 08/02/24 | 06/02/25 | 05/02/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.24x | 18.26x | -1.2x | - | 4.62Cr | |
| 104.61x | 5.85x | 24.81x | 2.37% | 35TCr | |
| 22.16x | 3.01x | 10.52x | 1.79% | 6.57TCr | |
| 14.74x | 7.23x | 11.08x | - | 1.21TCr | |
| 14.3x | 1.78x | 6.04x | 3.1% | 756.43Cr | |
| 18.54x | 5.75x | 15.33x | -.--% | 448.85Cr | |
| 38.87x | 2.49x | 28.55x | 0.72% | 434.16Cr | |
| 33.24x | 5.22x | 15.29x | - | 289.52Cr | |
| -206.4x | - | - | -.--% | 239.95Cr | |
| Average | 4.32x | 6.20x | 13.80x | 1.33% | 5.05TCr | |
| Weighted average by Cap. | 85.21x | 5.37x | 21.93x | 2.25% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ORX Stock
- Valuation Orexo AB
Select your edition
All financial news and data tailored to specific country editions
